Svb Leerink upgraded shares of Solid Biosciences (NASDAQ:SLDB) from a market perform rating to an outperform rating in a research note issued to investors on Monday, BenzingaRatingsTable reports. The brokerage currently has $15.00 price target on the stock, up from their previous price target of $8.00. Svb Leerink also issued estimates for Solid Biosciences’ Q3 2019 earnings at ($0.58) EPS, Q4 2019 earnings at ($0.55) EPS, FY2019 earnings at ($2.68) EPS, Q1 2020 earnings at ($0.52) EPS, Q2 2020 earnings at ($0.49) EPS, Q3 2020 earnings at ($0.46) EPS, Q4 2020 earnings at ($0.40) EPS, Q4 2020 earnings at ($0.45) EPS, FY2020 earnings at ($1.85) EPS, FY2020 earnings at ($1.91) EPS, FY2021 earnings at ($1.85) EPS, FY2021 earnings at ($1.50) EPS, FY2022 earnings at ($1.46) EPS, FY2022 earnings at ($2.06) EPS, FY2023 earnings at ($1.26) EPS and FY2023 earnings at ($0.81) EPS.

Several other research firms have also weighed in on SLDB. Chardan Capital raised Solid Biosciences from a neutral rating to a buy rating and upped their target price for the company from $7.50 to $10.00 in a report on Friday, August 16th. ValuEngine raised Solid Biosciences from a hold rating to a buy rating in a report on Thursday, August 1st. Goldman Sachs Group lowered Solid Biosciences from a neutral rating to a sell rating and lowered their target price for the company from $5.00 to $4.00 in a report on Tuesday, May 14th. Citigroup set a $6.00 target price on Solid Biosciences and gave the company a hold rating in a report on Thursday, May 16th. Finally, Credit Suisse Group lowered Solid Biosciences from a neutral rating to an underperform rating and lowered their target price for the company from $7.00 to $6.00 in a report on Tuesday, May 14th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. Solid Biosciences currently has a consensus rating of Hold and an average target price of $8.21.

Solid Biosciences stock opened at $9.03 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.73 and a current ratio of 5.73. The firm has a market capitalization of $329.27 million, a price-to-earnings ratio of -4.01 and a beta of 2.07. Solid Biosciences has a fifty-two week low of $4.32 and a fifty-two week high of $54.54. The stock’s fifty day moving average is $5.95 and its two-hundred day moving average is $7.81.

Solid Biosciences (NASDAQ:SLDB) last posted its earnings results on Wednesday, August 14th. The company reported ($0.76) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.05. As a group, sell-side analysts forecast that Solid Biosciences will post -3.05 EPS for the current fiscal year.

In related news, Director Life Sciences Maste Perceptive acquired 2,822,581 shares of Solid Biosciences stock in a transaction dated Thursday, July 25th. The shares were acquired at an average cost of $4.65 per share, for a total transaction of $13,125,001.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 31.20% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the company. Walleye Trading Advisors LLC bought a new position in Solid Biosciences during the 2nd quarter worth approximately $210,000. Walleye Trading LLC bought a new position in Solid Biosciences during the 2nd quarter worth approximately $214,000. Cubist Systematic Strategies LLC bought a new position in Solid Biosciences during the 2nd quarter worth approximately $70,000. AQR Capital Management LLC bought a new position in Solid Biosciences during the 2nd quarter worth approximately $255,000. Finally, EcoR1 Capital LLC bought a new position in Solid Biosciences during the 2nd quarter worth approximately $4,755,000. Institutional investors and hedge funds own 60.06% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

See Also: What are defining characteristics of a correction?

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.